Response to primary canine core vaccination in 10-month-old seronegative dogs treated with three times the recommended therapeutic dose of Ilunocitinib tablets (Zenrelia™)

Considering the mechanism of JAK inhibitors, it is not surprising dogs receiving three times the expected dose of drug had higher incidence of parasitic and viral disease compared to controls. In the face of these confounding infectious diseases, it was also not surprising that treated dogs had lower measures of health status correlating directly to both disease severity and inactivated vaccine response. Although confounding disease prevents a definitive conclusion regarding the original intent of the study, it was interesting that there was sufficient threshold response relating to the initial modified live vaccination across both control and Jak inhibitor treated groups administered on day 28, however this was not the primary endpoint of the study.